Using synthetic DNA to create viral particles for better vaccine responses
Investigation of Synthetic DNA-based Viral Particles for Spatially Controlled Antigen Presentation
This study is looking at a new way to make vaccines work better against tough viruses like HIV by using tiny particles made from synthetic DNA to help your immune system recognize and fight these viruses more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts Institute of Technology NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-10884259 on NIH RePORTER |
What this research studies
This research focuses on improving vaccine effectiveness against challenging viruses like HIV by using synthetic DNA to create nanoparticles that present antigens in a controlled manner. By engineering these nanoparticles, the study aims to enhance the immune response, specifically the activation of B cells, which are crucial for producing antibodies. The researchers will explore how different characteristics of these nanoparticles, such as size and antigen arrangement, influence the immune response. This innovative approach could lead to more effective subunit vaccines for infectious diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for HIV or those who may benefit from improved vaccine strategies against infectious diseases.
Not a fit: Patients who are not at risk for HIV or who have already been effectively vaccinated against it may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective vaccines that provide better protection against HIV and potentially other infectious diseases.
How similar studies have performed: Previous research has shown promise in using nanoparticle-based vaccines, indicating that this approach could lead to significant advancements in vaccine development.
Where this research is happening
Cambridge, United States
- Massachusetts Institute of Technology — Cambridge, United States (Active)
Researchers
- Principal investigator: Bathe, Mark — Massachusetts Institute of Technology
- Study coordinator: Bathe, Mark
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.